基于PET/CT影像组学特征评估非小细胞肺癌患者PD-L1表达水平的初步结果
本研究纳入399例I-IV期非小细胞肺癌患者,从PET/CT图像提取影像组学特征并构建模型预测PD-L1表达状态。CT来源特征模型预测PD-L1(SP142)表达>1%的AUC为0.97,>50%为0.80;预测PD-L1(28-8)表达>1%的AUC为0.86,>50%为0.91。作者认为基于影像组学的方法尤其是CT来源模型可能较准确预测PD-L1表达状态,值得进一步分析。
要点
- CT来源影像组学模型预测PD-L1(SP142)表达>1%的AUC达0.97,>50%为0.80。
- CT来源模型预测PD-L1(28-8)表达>1%的AUC为0.86,>50%为0.91。
- PET来源模型预测效能较低,各任务AUC为0.61-0.75。
核心结论
- 基于影像组学的预测方法,尤其是CT来源预测模型,可能相对准确地预测非小细胞肺癌患者的PD-L1表达状态。
- 该方法可能有助于指导临床实践中的免疫治疗,值得进一步分析。
研究设计与样本
- 研究纳入399例I-IV期非小细胞肺癌患者,行PET/CT图像采集后对肿瘤进行分割以选取 essential 原发灶。
- 提取影像组学特征后,采用自动相关决定(automatic relevance determination)滤波,并基于PD-L1表达状态的相关性用LASSO模型进行特征精简。
- 分别基于CT、PET和PET/CT图像特征构建预测模型,用于区分特定PD-L1类型的表达状态;采用五折交叉验证评估模型准确性,并计算每个模型的受试者工作特征曲线及相应曲线下面积(AUC)。
诊断标准与关键数值
- 共筛选出24个与PD-L1表达水平显著相关的特征,并据此构建和比较了CT、PET、PET/CT来源特征的模型。
- 预测PD-L1(SP142)表达>1%:CT、PET、PET/CT特征模型的AUC分别为0.97、0.61、0.97。
- 预测PD-L1(SP142)表达>50%:CT、PET、PET/CT特征模型的AUC分别为0.80、0.65、0.77。
- 预测PD-L1(28-8)表达>1%:CT、PET、PET/CT特征模型的AUC分别为0.86、0.62、0.85。
- 预测PD-L1(28-8)表达>50%:CT、PET、PET/CT特征模型的AUC分别为0.91、0.75、0.88。
临床应用与阅片要点
- 作者认为基于影像组学的预测方法,尤其是CT来源预测模型,可能相对准确地预测非小细胞肺癌患者的PD-L1表达状态。
- 作者认为该方法可能有助于指导临床实践中的免疫治疗,值得进一步分析。
局限性
- 原文结论指出该影像组学预测方法值得进一步分析(deserves further analysis)。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
英文原文(摘要)· 点击展开
RATIONALE AND OBJECTIVES: To explore the potential value of radiomic features-derived approach in assessing PD-L1 expression status in nonsmall cell lung cancer (NSCLC) patients.
MATERIALS AND METHODS: A cohort of 399 stage I-IV NSCLC patients were enrolled. Tumor segmentation was performed to select essential primary lesions of NSCLC cases after PET/CT images acquisition. Features were extracted, then filtered with automatic relevance determination and minimized with LASSO model based on its relevance of PD-L1 expression status. Finally, we built predictive models with features from the CT, the PET, and the PET/CT images, respectively, for differentiating different status of specific PD-L1 types. Five-fold cross validation was practiced to evaluate the signatures' accuracy, and the receiver operating characteristic as well as the corresponding area under the curve (AUC) was reckoned for each model.
RESULTS: With the total of 24 selected features which were significantly associated with PD-L1 expression levels, models based on CT-, PET-, PET/CT-derived features were built and compared. For PD-L1 (SP142) expression level over 1% prediction, models that comprised radiomic features from the CT, the PET, and the PET/CT images resulted in an AUC of 0.97, 0.61, and 0.97, respectively; models for over 50% prediction resulted with AUC of 0.80, 0.65, and 0.77. For PD-L1 (28-8) expression level prediction, predictive models of over 1% expression scored at 0.86, 0.62, and 0.85; and signatures of over 50% expression reached the score of AUCs at 0.91, 0.75, and 0.88, respectively.
CONCLUSION: The radiomic-based predictive approach, especially CT-derived predictive model, may anticipate PD-L1 expression status in NSCLC patients relatively accurate. It may be helpful in guiding immunotherapy in clinical practice and deserves further analysis.
引用
- Jiang M, Sun D, Guo Y, et al. Assessing PD-L1 Expression Level by Radiomic Features From PET/CT in Nonsmall Cell Lung Cancer Patients: An Initial Result. Acad Radiol. 2019. PMID: 31147234. doi:10.1016/j.acra.2019.04.016
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。